Evofem Biosciences, Inc. (EVFM)
Chart Events
Performance Outlook
| Previous Close | 0.3719 |
| Open | 0.6838 |
| Bid | 0.8862 x 3100 |
| Ask | 0.8820 x 1300 |
| Day's Range | 0.5900 - 0.9580 |
| 52 Week Range | 0.2750 - 18.6000 |
| Volume | |
| Avg. Volume | 3,686,539 |
| Market Cap | 33.418M |
| Beta (5Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.0060 |
| Earnings Date | Aug 09, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.10 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EVFM
Related Research
- Evofem Biosciences, Inc.Daily – Vickers Top Insider Picks for 09/10/2021The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat10 months agoArgus Research
- MarketWatch
Evofem's stock jumps 30% after Supreme Court decision on Roe v. Wade
Shares of Evofem Biosciences Inc. soared 30.6% in trading on Friday, hours after the Supreme Court decision striking down Roe v. Wade was announced. Experts have speculated that the court's decision could lead to restrictions on birth control in the future although that was not included in Friday's decision. Evofem makes a non-hormonal gel that is used about an hour before sex to prevent pregnancy by controlling pH levels, which in turn lessens the mobility of sperm. It is prescribed by health c
- PR Newswire
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.
- ACCESSWIRE
Traders News Source Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
NEW YORK, NY / ACCESSWIRE / June 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. Mark Roberts, Senior Editor at Traders News Source had the opportunity to conduct the interview featuring Evofem Biosciences, Inc.
